Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Black Diamond Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.blackdiamondthe...
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Mark A. Velleca, MD, PhD
Number Of Employees: 24
Enterprise Value: $41,371,714
PE Ratio: -1.17
Exchange/Ticker 1: NASDAQ:BDTX
Exchange/Ticker 2: N/A
Latest Market Cap: $84,426,696
BioCentury | Apr 2, 2025
Management Tracks
Change at the top for Phathom as Basta replaces Curran
Plus: Updates from Nuage, GV, Inhibrx, Lyell, Repare, Adcendo, ITM Isotope, Transgene and Novartis
BioCentury | Mar 18, 2025
Management Tracks
Zenas names Lisa von Moltke head of R&D and CMO
Plus: CBC’s Lan Kang becomes CEO of Azkarra, and updates from Ionctura, Sunbird and Surf Bio
BioCentury | Oct 21, 2024
Product Development
EGFR: A best-in-class strategy study
The target is one of industry’s most notable case studies in continued product differentiation and market growth
BioCentury | Sep 25, 2024
Product Development
Wave claims early lead in second-generation exon 53 skipping
In BioCentury’s latest Clinical Report, Wave gains on DMD data, plus updates from Daiichi and AZ, Black Diamond, Metsera, Biohaven and more
BioCentury | Apr 30, 2024
Management Tracks
New CEOs at Evox and George Medicines
Plus: Stoke hires Thomas Leggett as CFO, and updates from TScan, Rinri, Tevogen and more
BioCentury | Sep 18, 2023
Management Tracks
Peter Bains named group CEO at Biocon
Plus: CEO changes at Lonza and Black Diamond, and updates from ImmunoGen, BenevolentAI and Nilogen
BioCentury | Sep 11, 2023
Management Tracks
Sanofi alum Sibold named CEO at Madrigal
Plus: Fenimore to succeed Landry as Regeneron CFO and updates from SpringWorks, SalioGen, Oxular, Solu, Flagship, Oculis
BioCentury | Jul 1, 2023
Finance
June 30 Quick Takes: Genfit hits but falls short of competitor in primary biliary cholangitis
Plus: Novartis sells front-of-eye portfolio to B&L, and updates from argenx, Black Diamond, KangaBio and more
BioCentury | Jun 27, 2023
Product Development
June 27 Quick Takes: FDA denies Regeneron’s high-dose Eylea
Plus: Sanofi meets in atopic dermatitis and updates from Nkarta, Astraveus and more
BioCentury | Dec 13, 2022
Product Development
Dec. 12 Quick Takes: Setbacks at ASH for Adicet and Lava
Plus: Updates from Magenta, CSL, Hemgenix, Affimed, Kymera and more
Items per page:
1 - 10 of 53